低危和中危前列腺癌异质性剂量立体定向体部放疗的2期多中心试验:5年结局
这项单臂前瞻性2期试验纳入259例低危或中危前列腺癌患者,来自美国18个中心,2007年12月至2012年2月接受38Gy分4次立体定向体部放疗,中位随访5年。5年无生化复发率低危组100%、中危组88.5%,晚期泌尿生殖道和胃肠道毒性低,但尿控域在24个月后下降、性功能随时间降低。作者认为该方案对选择恰当的低危或中危前列腺癌患者有效。
要点
- 低危组5年无生化复发率100%,中危组88.5%。
- 5年累积2级、3级、4级泌尿毒性分别为12.4%、1.9%、0.4%。
- 5年累积2级、3级、4级胃肠道毒性分别为3.4%、0%、0%。
核心结论
- 该38Gy分4次立体定向体部放疗方案无生化复发生存率高,中位PSA最低点极低提示前列腺消融。
- 作者认为对于选择立体定向体部放疗的恰当低危或中危前列腺癌患者,该治疗方案有效。
研究设计与样本
- 单臂前瞻性2期试验,纳入259例低危或中危前列腺癌患者,来自美国18个中心,治疗时间2007年12月至2012年2月,中位随访5年(四分位距37-85个月)。
- 干预为38Gy分4次立体定向体部放疗,放疗计划模拟高剂量率近距离放疗剂量学。
主要发现
- 5年无生化复发率低危组为100%,中危组为88.5%。
- 5年累积2级、3级、4级泌尿毒性分别为12.4%、1.9%、0.4%。
- 5年累积2级、3级、4级胃肠道毒性分别为3.4%、0%、0%。
- 中位基线PSA为5.12ng/ml,至≥42个月时降至0.1ng/ml。
- 生活质量评分1个月时下降,6个月时恢复基线;24个月后尿控域下降(基线使用尿垫2%,5年时10%),性功能随时间降低。
关键数值与推荐
- 5年累积泌尿毒性2级12.4%、3级1.9%、4级0.4%。
- 5年累积胃肠道毒性2级3.4%、3级0%、4级0%。
- 中位PSA从基线5.12ng/ml降至≥42个月时的0.1ng/ml。
- 尿垫使用率基线2% vs 5年10%(5年较基线升高8个百分点)。
临床怎么用
- 作者认为对于选择立体定向体部放疗的恰当低危或中危前列腺癌患者,该治疗方案有效。
局限性
- 该试验非随机,与其他类型放疗的比较结果难以进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radiation therapy is an emerging treatment for prostate cancer (PC), with potential biological and oncologic advantages. A well-established radiation dosing schedule (38Gy in 4 fractions) has shown excellent long-term efficacy in high-dose-rate (HDR) brachytherapy. OBJECTIVE: To report 5-yr efficacy, toxicity, and quality-of-life (QOL) outcomes of a novel 4-d SBRT regimen. DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm prospective phase 2 trial involving 259 patients with low- or intermediate-risk PC treated at 18 US centers from December 2007 to February 2012. The median follow-up was 5yr (interquartile range 37-85mo). INTERVENTION: SBRT with 38Gy in four fractions; radiation plans mimicked HDR brachytherapy dosimetry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured freedom from biochemical recurrence (BCR) and assessed toxicities using the Common Terminology Criteria for Adverse Events v3.0 and QOL using the Expanded Prostate Cancer Index Composite. RESULTS AND LIMITATIONS: The 5-yr BCR-free rates were 100% and 88.5% for patients with low- and intermediate-risk PC, respectively. The cumulative 5-yr grade 2, 3, and 4 toxicity rates were 12.4%, 1.9%, and 0.4% for urinary, and 3.4%, 0%, and 0% for gastrointestinal toxicities, respectively. The median baseline prostate-specific antigen (PSA) level of 5.12ng/ml decreased to 0.1ng/ml by ≥42mo. QOL scores decreased at 1mo but returned to baseline by 6mo, with a later decline (≥24mo) in the urinary continence domain (pad use was 2% at baseline and 10% at 5yr), and lower sexual potency over time. Comparative outcomes versus other types of radiotherapy are difficult because the trial was not randomized. CONCLUSIONS: This regimen yields a high rate of BCR-free survival, with a very low median PSA nadir suggesting prostate ablation. For properly selected patients with low- or intermediate-risk PC who choose SBRT, this treatment regimen is effective. PATIENT SUMMARY: This potent four-treatment stereotactic body radiotherapy regimen appears to be effective for patients with early prostate cancer.
引用
- Fuller DB, Falchook AD, Crabtree T, et al. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. Eur Urol Oncol. 2018. PMID: 31158102. doi:10.1016/j.euo.2018.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。